伊藤拓水

イトウタクミ | Ito Takumi

競争的資金等の研究課題 (4件)：

論文 (27件)：

Kiwamu Hatakeyama, Yoshikane Kikushige, Daisuke Ishihara, Shunsuke Yamamoto, Gentaro Kawano, Taro Tochigi, Toshihiro Miyamoto, Teppei Sakoda, Andy Christoforou, Yuya Kunisaki, et al. Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drugs-induced thromboembolism. Blood advances. 2024
Takumi Ito. Protein degraders -from thalidomide to new PROTACs. The Journal of Biochemistry. 2023
Takumi Ito, Tomoko Asatsuma-Okumura, Akinori Endo, Junichi Yamamoto, Yoshiko Iwai, Yuki Yamaguchi, Mikihiko Naito, Hiroshi Handa, Yasushi Saeki. ZNF276 and WIZ are CRBN neosubstrates involved in the anti-angiogenic activity of thalidomide and immunomodulatory drugs. 2023
Akihiro Kimura, Takeshi Takagi, Thiprampai Thamamongood, Satoshi Sakamoto, Takumi Ito, Iwao Seki, Masahiro Okamoto, Hiroyuki Aono, Satoshi Serada, Tetsuji Naka, et al. Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4. Annals of the rheumatic diseases. 2023
Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chemical Society Reviews. 2022. 51. 15. 6234-6250

MISC (16件)：

朝妻知子, 半田宏, 伊藤拓水. 多発性骨髄腫および類縁疾患の病態解析と治療の進歩新たなcereblon modulator(CELMoD)の開発とその標的分子. 月刊血液内科. 2022. 84. 4
伊藤拓水, 朝妻知子, 半田宏. Targeted Protein Degradation 標的タンパク質分解誘導分子. 月刊細胞. 2021. 53. 3
Mitsuhito Hirano, Yoichi Imai, Takahiko Murayama, Kota Sato, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Noriko Gotoh, et al. Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma. BLOOD. 2019. 134
清水誠之, 伊藤拓水, 半田宏. プロテアソームと疾病研究の動向セレブロンモジュレーターによるタンパク質分解誘導創薬. 月刊メディカル・サイエンス・ダイジェスト. 2019. 45. 4
Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Koiti Inokuchi, Hidemi Takahashi, Hideto Tamura. Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab. BLOOD. 2018. 132

学歴 (2件)：

経歴 (5件)：

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

伊藤 拓水